{'fraction_non_alphanumeric': 0.039631988676574664, 'fraction_numerical': 0.005661712668082095, 'mean_word_length': 5.830917874396135, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 3, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prostacyclin Release from Stem Cell Derived Endothelial Cells

Stem cell‐derived endothelial cells are being investigated as potential therapies. Endothelial cells for therapy can be isolated from human embryo (hESC‐EC), circulating progenitors (EPC) or induced pluripotent stem cells (iPS‐EC). Endothelial cells in vessels release the cardioprotective hormone prostacyclin, which is essential for organ homeostasis and a function to be preserved in organ regeneration programs. Prostacyclin is formed from arachidonic acid by the concerted actions of cyclooxygenase (COX) and prostacyclin synthase. Here we have compared the ability of endothelial cells derived from key stem cell phenotypes to release prostacyclin with adult endothelial cells from the lung (HMVEC). hESC‐EC, EPC (late outgrowth), iPS‐EC and HMVEC were treated for 24h +/− LPS (1μg/ml) or IL‐1β (1ng/ml) to activate prostacyclin release. Prostacyclin was measured as its breakdown product 6‐ketoPGF1α by ELISA. Endothelial cells from different phenotypes of stem cells are capable of releasing prostacyclin. The relative efficacy for prostacyclin release was EPC>;HMVEC>;iPS‐EC>;hESC‐EC (Figure 1). These observations show that, of the stem cell progenitors available, EPC‐derived endothelial cells have the greatest propensity to release prostacyclin. These observations may have important relevance in the use of engineered endothelial cells.